Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Fixed Dose, Dose-response Study of Ropinirole Prolonged Release (PR) as Adjunctive Treatment to L-dopa in Patients With Advanced Parkinson's Disease

NCT01494532 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01494532
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01494532 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Fixed Dose, Dose-response Study of Ropinirole Prolonged Release (PR) as Adjunctive Treatment to L-dopa in Patients With Advanced Parkinson's Disease
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Completed
Start date
April 2, 2012
Completion date
November 18, 2014
Enrollment
352 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease